scholarly article | Q13442814 |
P2093 | author name string | Katoh H | |
Miyasaka Y | |||
Fujita M | |||
Fujioka Y | |||
Morita T | |||
Horita S | |||
Nagashima K | |||
Hida Y | |||
P433 | issue | 3B | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2257-2260 | |
P577 | publication date | 1999-05-01 | |
P1433 | published in | Anticancer Research | Q326290 |
P1476 | title | Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas | |
P478 | volume | 19 |
Q47861428 | A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma |
Q38650019 | Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers |
Q35640101 | Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future |
Q36287599 | Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial |
Q42818294 | Chemotherapy in gallbladder carcinoma |
Q89170919 | Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial |
Q36614705 | Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma |
Q35583920 | Current management of gallbladder carcinoma |
Q33372792 | EGFR expression in gallbladder carcinoma in North America |
Q38642455 | Emerging molecular targets and therapy for cholangiocarcinoma |
Q37765099 | Genetics of biliary tract cancers and emerging targeted therapies |
Q38686339 | Immunotherapy of biliary tract cancer |
Q38619219 | New Horizons for Precision Medicine in Biliary Tract Cancers |
Q90308323 | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma |
Q38160836 | New and emerging treatment options for biliary tract cancer |
Q84792092 | Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma |
Q42635172 | Targeted medical therapy of biliary tract cancer: recent advances and future perspectives |
Q30398807 | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option |
Q35000785 | Targeting metastatic upper gastrointestinal adenocarcinomas |
Q44660500 | Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas |
Search more.